S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
OTCMKTS:SGIOF

Shionogi & Co., Ltd. (SGIOF) Stock Price, News & Analysis

$53.50
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$53.50
$53.50
50-Day Range
$46.21
$53.50
52-Week Range
$40.46
$53.50
Volume
36 shs
Average Volume
300 shs
Market Capitalization
N/A
P/E Ratio
0.59
Dividend Yield
35.70%
Price Target
N/A
SGIOF stock logo

About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOF)

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

SGIOF Stock Price History

SGIOF Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
See More Headlines
Receive SGIOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:SGIOF
Fax
N/A
Employees
5,680
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Isao Teshirogi Ph.D. (Age 65)
    CEO, President & Representative Director
    Comp: $1.95M
  • Susumu Mitsumori
    Vice President of Finance & Accounting Department
  • Mr. Kazuhiro Hatanaka
    Senior Executive Officer & Senior VP of Administration Division
  • Mr. Takeshi Shiota Ph.D.
    Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.
  • Mr. Yoshimasa Kyokawa
    Vice President of Corporate Communications & Secretary Office
  • Yoshihiro Furuya
    Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office
  • Mr. Kohji Hanasaki Ph.D.
    Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business Division
  • Dr. John A. Keller Ph.D. (Age 59)
    Senior Executive Officer and Senior VP of R&D Supervisory Unit
  • Akira Kato Ph.D.
    Corporate Officer & President of Shionogi Pharma Co., Ltd
  • Dr. Ryuichi Kiyama Ph.D.
    Senior Executive Officer & Senior VP of Corporate Strategy Division

SGIOF Stock Analysis - Frequently Asked Questions

How have SGIOF shares performed in 2024?

Shionogi & Co., Ltd.'s stock was trading at $46.21 at the start of the year. Since then, SGIOF stock has increased by 15.8% and is now trading at $53.50.
View the best growth stocks for 2024 here
.

Are investors shorting Shionogi & Co., Ltd.?

Shionogi & Co., Ltd. saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 504,000 shares, an increase of 44.7% from the February 14th total of 348,300 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 5,040.0 days.
View Shionogi & Co., Ltd.'s Short Interest
.

Is Shionogi & Co., Ltd. a good dividend stock?

Shionogi & Co., Ltd. (OTCMKTS:SGIOF) pays an annual dividend of $19.10 per share and currently has a dividend yield of 1.14%. The dividend payout ratio is 21.00%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SGIOF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners